Cancer

This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.

Primary disease category: 

This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases:

Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension

Primary disease category: 

This is an open-label, multi-center, randomized, Phase 3 study designed to compare the efficacy and safety of AM0010 in combination with FOLFOX versus FOLFOX alone in patients with metastatic adenocarcinoma of the pancreas who have progressed on one prior gemcitabine containing regimen.

Primary disease category: 

The purpose of this study is to assess the safety and tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in patients with B-cell malignancies.

Primary disease category: 

The purpose of this study is to evaluate the safety, pharmacokinetics and efficacy of Venetoclax as a single-agent and in combination with Azacitidine in subjects with high-risk myelodysplastic syndromes after hypomethylating agent-failure

Primary disease category: 

Pages

Subscribe to RSS - Cancer